| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.057 | 0.5 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.043 | 0.5 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | R428 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.5 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.037 | 0.5 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |